In line with this, Dey et al. found that while the mRNA and protein levels of FOXO3a were increased in response to estrogen receptor expression in prostate cancer cells, the phosphorylation of FOXO3a remained unchanged. The gene discussed is FOXO3; the disease is prostate carcinoma.